Pulmocide Ltd. (“the Company”), a late-stage biopharmaceutical company focused on the development of a novel inhaled azole therapy for patients at risk of developing serious complications associated with aspergillosis, today announced a $3.5 million investment from the Cystic Fibrosis Foundation for the development of opelconazole for lung transplant recipients. People with cystic fibrosis (CF), particularly those who have undergone lung transplants, are highly susceptible to invasive Aspergillus fungal infections in their airways. Opelconazole is a novel azole specifically designed for inhaled use to prevent and treat pulmonary aspergillosis with potentially fewer side effects than standard-of-care azole treatments.
The full text of the press release can be found here.